Trials and tribulations in the removal of dextropropoxyphene from the Australian Register of Therapeutic Goods

Nick A Buckley and Thomas A Faunce
Med J Aust 2013; 199 (4): 257-260. || doi: 10.5694/mja13.10040
  • Nick A Buckley1
  • Thomas A Faunce2

  • 1 Medical Professorial Unit, Prince of Wales Hospital Clinical School, Sydney, NSW.
  • 2 College of Medicine, Biology and Environment and ANU College of Law, Australian National University, Canberra, ACT.


Competing interests:

Nick Buckley was an expert witness at the AAT appeal against the delisting of dextropropoxyphene; he is also a member of the Advisory Committee on the Safety of Medicines and the Chairman of the Editorial Advisory Board of the Australian Medicines Handbook.

  • 1. Aspen Pharmacare Australia Pty Ltd and Minister for Health and Ageing [2012] AATA 362 (15 June 2012). Last updated Aug 2012. (accessed Jan 2013).
  • 2. Therapeutic Goods Administration. TGA to cancel four prescription pain-killers from 1 March 2012. TGA, 2 Dec 2011. (accessed Jan 2013).
  • 3. Finkle BS. Self-poisoning with dextropropoxyphene and dextropropoxyphene compounds: the USA experience. Hum Toxicol 1984; 3 Suppl: 115S-134S.
  • 4. Hawton K, Bergen H, Simkin S, et al. Six-year follow-up of impact of co-proxamol withdrawal in England and Wales on prescribing and deaths: time-series study. PLOS Med 2012; 9: e1001213.
  • 5. Rossi S, editor. The Australian medicines handbook: AMH. Adelaide: The Australian Medicines Handbook Unit Trust, 2000.
  • 6. Therapeutic Guidelines Expert Writing Group. Therapeutic guidelines: analgesic. Version 4. Melbourne: Therapeutic Guidelines Ltd, 2002.
  • 7. Aspen Pharmacare Australia Pty Ltd and Minister for Health and Ageing [2013] AATA 197 (5 April 2013). Last Updated: 10 Apr 2013. (accessed Apr 2013).
  • 8. Administrative Appeals Tribunal. What we do. (accessed Aug 2013).
  • 9. Administrative Appeals Tribunal of Australia. [Database of decisions]. Australasian Legal Information Institute. (accessed Jan 2013).
  • 10. Shirlow E, Faunce T. Recent legal developments and the authority of the Australian Therapeutic Goods Administration. J Law Med 2009; 16: 764-769.
  • 11. Hamburg MA. Shattuck lecture. Innovation, regulation, and the FDA. N Engl J Med 2010; 363: 2228-2232.
  • 12. Therapeutic Goods Administration. Note for guidance on good clinical practice (CPMP/ICH/135/95). TGA, 2000. (accessed Jan 2013).
  • 13. Runciman WB, Hunt TD, Hannaford NA, et al. CareTrack: assessing the appropriateness of health care delivery in Australia. Med J Aust 2012; 197: 100-105. <MJA full text>
  • 14. Ratanawijitrasin S, Wondemagegnehu E. Effective drug regulation: a multicountry study. World Health Organization, 2002.
  • 15. Committee on Ethical and Scientific Issues in Studying the Safety ofApproved Drugs, Board on Population Health and Public Health Practice, Institute of Medicine. Ethical and scientific issues in studying the safety of approved drugs. Washington, DC: National Academies Press, 2012.
  • 16. US Food and Drug Administration. About FDA. CDER Ombudsman. MedicalProducts andTobacco/CDER/ContactCDER/CDEROmbudsman (accessed Jan 2013).
  • 17. Hamburg MA. The growing role of epidemiology in drug safety regulation. Epidemiology 2011; 22: 622-624.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.